Clinical Trial Update: Endocardial Delivery for Myocardial Regeneration Using Allogeneic iPSC-derived Cardiomyocyte Spheroids for HF With Systolic Dysfunction (EMERALD Study) [Phase 1, Phase 2]

View source ↗

Summary

The EMERALD study is evaluating endocardial delivery of allogeneic iPSC-derived cardiomyocyte spheroids for heart failure with systolic dysfunction in Phase 1/2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dilated Cardiomyopathy
• Heart Failure
• Ischemic Heart Disease
• Ischemic Heart Failure

Drugs mentioned

• Allogeneic iPSC-derived cardiomyocyte spheroids (iPSC-derived cardiomyocyte spheroids)

Snippet

Sponsor: Heartseed Inc. | Conditions: Heart Failure, Ischemic Heart Failure | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING